Key facts
- RegenMed’s last known valuation is $20.3M (Jan 2025).
- It has raised $550K across 1 recorded rounds; the latest was Seed Round ($290K) in Feb 2025.
- RegenMed has filed 1 Form D with the SEC, most recently Feb 2025 ($290K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for RegenMed
Funding rounds
1 roundsAbout RegenMed
Operator of a software platform intended to aggregate and license longitudinal real-world data from primary healthcare sources. The company offers a patented platform with direct data sourcing, clear dataset ownership rights, and structured data licensing capabilities, enabling product manufacturers, healthcare providers, and research organizations to access reliable data for analysis and decision making.
- Sector
- Healthcare
- HQ
- Greenwich, CT, United States
- Founded
- 2014
- Employees
- 20
- Website
- rgnmed.com/
- Ownership
- Privately Held (backing)
RegenMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RegenMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RegenMed in its N-PORT filings yet. We sweep new filings monthly.